SLC5A2 and hydrops fetalis: The 2021 ESC Guidelines for the Management and Treatment of Acute and Chronic Heart Failure recommended SGLT2 inhibitors for patients with type 2 diabetes mellitus (T2DM) at risk of cardiovascular (CV) events, citing their ability to reduce heart failure (HF) hospitalization, major CV events, and CV death.